Skip to content
Life Sciences Series A Founded 2021

Biomemory

Biomemory provides bio-digital data storage solutions, developing a petrol-free DNA synthesis and copy process based on synthetic biology for long-term data storage. The platform enables the production of long, bio-sourced, biocompatible, and bio-secure DNA fragments that can be stored as inert polymers for thousands of years without any energy input. Founded in 2021 and headquartered in Paris, France, Biomemory has…

📍 Paris, France · Genomics

Funding snapshot

Last roundSeries A
Amount$18M
Date10 December 2024
Total raised$23M
Team size77

About

Biomemory provides bio-digital data storage solutions, developing a petrol-free DNA synthesis and copy process based on synthetic biology for long-term data storage. The platform enables the production of long, bio-sourced, biocompatible, and bio-secure DNA fragments that can be stored as inert polymers for thousands of years without any energy input. Founded in 2021 and headquartered in Paris, France, Biomemory has raised approximately $23.2M in Series A funding from investors including eureKARE, Credit Mutuel Innovation, Bpifrance, Next Sequence, Sorbonne Venture, and Accelerem. The company employs 77 people and addresses the growing challenge of sustainable long-term data archiving by encoding digital information into synthetic DNA molecules, offering storage density and durability orders of magnitude beyond conventional magnetic and optical media while eliminating the energy costs associated with maintaining data center archives.

Business model

Genomics > Applied Genomics > DNA Data Storage

Institutional investors

eureKARE La French Tech Paris Business Angels castle-studio.com Crédit Mutuel Innovation Bpifrance Next Sequence Groupe Prunay Blast.Club Sorbonne Venture Adnexus Accelerem Credit Mutuel Equity Octave Klaba Flavien Kulawik

Latest coverage

No articles yet.

Raising like Biomemory?

Analyze your pitch deck before your next raise.

Analyze My Deck →